UGC Approved Journal no 63975(19)
New UGC Peer-Reviewed Rules

ISSN: 2349-5162 | ESTD Year : 2014
Volume 12 | Issue 10 | October 2025

JETIREXPLORE- Search Thousands of research papers



WhatsApp Contact
Click Here

Published in:

Volume 12 Issue 5
May-2025
eISSN: 2349-5162

UGC and ISSN approved 7.95 impact factor UGC Approved Journal no 63975

7.95 impact factor calculated by Google scholar

Unique Identifier

Published Paper ID:
JETIR2505445


Registration ID:
561967

Page Number

d856-d863

Share This Article


Jetir RMS

Title

“Formulation, Development And Evaluation Of Immediate Release Tablet Of Eletriptan Hydrobromide An Antimigraine Drug”

Abstract

This research aims to develop and assess an immediate release tablet of the antimigraine drug, a potent medication for migraine relief. Various formulation strategies were explored to achieve a rapid start of action and improved compliance from the patient. Several criteria were assessed for the prepared tablets, including drug content, disintegration time, dissolution profile, and stability. The optimized formulation exhibited promising characteristics, suggesting its potential as an effective treatment option for migraine patients. Migraine immediate-release tablets are designed to provide immediate relief from migraine symptoms. Most of these include drugs such as sumatriptan, zolmitriptan or rizatriptan, and Eletriptan, which acts as a vasoconstrictor constrict blood vessels in the brain and block pain pathways. These tablets are designed to be taken at the start of a migraine attack for quick relief. The immediate-release tablets were made with Eletriptan hydrobromide as the active pharmaceutical component. The direct compression method was used together with the proper excipients to create the tablets. Several formulation parameters were adjusted to achieve the desired drug release kinetics, disintegration time, and mechanical strength. Among other things, the tablets’ thickness, hardness, friability, disintegration time, and in vitro drug release were evaluated. All things considered, the recently developed Eletriptan hydrobromide immediate-release tablets serve as an effective treatment choice for the acute management of migraine, improving patient compliance and providing prompt relief from migraine symptoms.

Key Words

Potent, Sumatriptan, Zolmitriptan, rizatriptan, Eletriptan, Vasoconstrictor

Cite This Article

"“Formulation, Development And Evaluation Of Immediate Release Tablet Of Eletriptan Hydrobromide An Antimigraine Drug”", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.12, Issue 5, page no.d856-d863, May-2025, Available :http://www.jetir.org/papers/JETIR2505445.pdf

ISSN


2349-5162 | Impact Factor 7.95 Calculate by Google Scholar

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 7.95 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Cite This Article

"“Formulation, Development And Evaluation Of Immediate Release Tablet Of Eletriptan Hydrobromide An Antimigraine Drug”", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.12, Issue 5, page no. ppd856-d863, May-2025, Available at : http://www.jetir.org/papers/JETIR2505445.pdf

Publication Details

Published Paper ID: JETIR2505445
Registration ID: 561967
Published In: Volume 12 | Issue 5 | Year May-2025
DOI (Digital Object Identifier):
Page No: d856-d863
Country: KASHTI, MAHARASHTRA, India .
Area: Pharmacy
ISSN Number: 2349-5162
Publisher: IJ Publication


Preview This Article


Downlaod

Click here for Article Preview

Download PDF

Downloads

000174

Print This Page

Current Call For Paper

Jetir RMS